Positive CD133 expression correlates with poor prognosis in the NACRT group. A: The OS of the NACRT patients stratified by their CD133 expression status. The OS of the patients with positive CD133 expression was significantly worse than that of the patients with negative CD133 expression (median OS 17.6 mos for those showing positive CD133 expression vs. 41.1 mos for those showing negative CD133 expression; P = 0.0406). B: Overall survival for the NACRT patients stratified by their CD133 and ALDH1 expression status. The OS of the patients with CD133+/ALDH1- was significantly worse than that of the patients with the other markers’ expressions (median OS 12.1 mos for those showing CD133+/ALDH1- vs. 31.8 mos for those showing the other markers’ expressions; P = 0.0039).